A Federal Circuit panel on Tuesday vacated its earlier finding that Teva induced infringement of U.S. Patent No. RE40,000, GSK’s patent covering its drug, Coreg®, and set a new round of oral argument for February 23. Back in...more
After several years of delay, FDA announced this summer that it expects to publish new rules in April 2017 that will permit generic drug companies to make unilateral changes to their warning labels, even if the brand does...more
10/17/2016
/ Failure To Warn ,
Food and Drug Administration (FDA) ,
Generic Drugs ,
Labeling ,
Pharmaceutical Industry ,
PLIVA v Mensing ,
Preemption ,
Product Defects ,
Proposed Amendments ,
Proposed Regulation ,
Warning Labels